Brose, Marcia S.

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

Cabozantinib in Progressive Medullary Thyroid Cancer

Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology

Thyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatment

Cited by 1,217

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer

Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 522

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 476

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck

Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid Surgery

Cited by 117